Faricimabum (faricimab) is a bispecific antibody developed as an active pharmaceutical ingredient for use in the manufacture of therapies targeting retinal vascular diseases. It is designed to simultaneously bind to and inhibit both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2), addressing pathways involved in retinal neovascularization.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1607793-29-2
Vyleesi
pharmaceutical raw material
(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
pharmaceutical raw material
Norfentanyl
pharmaceutical raw material
Deucravacitinib
pharmaceutical raw material
[6-chloro-1-[2-(dimethylamino)ethyl]-2,3-dihydroindol-3-yl]-spiro[1H-2-benzofuran-3,4'-piperidine]-1'-ylmethanone
DRMVDBATNZBNEB-UHFFFAOYSA-N
CN(C)CCN1CC(C2=C1C=C(C=C2)Cl)C(=O)N3CCC4(CC3)C5=CC=CC=C5CO4